Ocera Therapeutics to Announce Third Quarter 2014 Financial Results

PALO ALTO, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its third quarter 2014 financial results on Thursday, November 13, 2014 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Thursday, November 13, 2014 at 4:30 p.m. Eastern Time.

To access the conference call via the Internet, go to www.ocerainc.com. To access the live conference call via phone, dial 877-317-6789. International callers may access the live call by dialing 412-317-6789. The reference name to enter the call is Ocera Therapeutics, Inc.

A replay of the call will be available for one month following the event. The replay of the conference call may be accessed on Thursday, November 13, 2014 after 8:00 p.m. Eastern Time, via the Internet, at www.ocerainc.com, or via phone at 877-344-7529 for domestic callers, or 412-317-0088 for international callers. The reference number to enter the replay of the call is 10055523.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.

CONTACT: Susan Sharpe Ocera Therapeutics, Inc. contact@ocerainc.com 919-328-1109

Source:Ocera Therapeutics, Inc.